Indivior PLC stock (GB00BYZ0C031): focus on addiction treatments after strong 2024 earnings

Indivior PLC has sharpened its focus on opioid use disorder and addiction therapies while reporting solid 2024 results and updating investors on its US listing strategy. What stands behind the specialty pharma stock’s story for US-focused investors?

Indivior PLC, a specialty pharmaceutical group focused on addiction treatment, continues to reshape its portfolio and capital structure after reporting robust 2024 results and providing an update on its US strategic priorities, including the planned transition of its primary listing to the United States, according to Indivior press release as of 02/13/2025.

In its full-year 2024 release, the company highlighted solid revenue growth in its opioid use disorder franchise and reiterated its focus on long-acting injectable therapies, while also outlining further steps for a potential US primary listing designed to deepen its access to American capital markets, according to Indivior press release as of 03/20/2025.

As of: 28.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Indivior
• Sector/industry: Specialty pharmaceuticals, addiction treatment
• Headquarters/country: United Kingdom
• Core markets: United States, selected international markets
• Key revenue drivers: Opioid use disorder therapies, long-acting injectables
• Home exchange/listing venue: Nasdaq (ticker: INDV), London Stock Exchange (secondary)
• Trading currency: USD on Nasdaq, GBP on LSE

Indivior PLC: core business model

Indivior PLC originates from the former addiction-treatment division of a larger consumer health group and has evolved into a focused specialty pharmaceutical business centered on opioid use disorder and related mental health conditions. The company’s strategy is to address substance use disorders with evidence-based pharmacotherapies coupled with medical support services, according to Indivior company profile as of 01/15/2025.

The core of Indivior’s model rests on branded medications that help patients manage dependence on opioids by reducing cravings and withdrawal symptoms. These treatments are prescribed in conjunction with counseling and broader addiction care programs, making the company a key player in medication-assisted treatment in the US market, according to Indivior product overview as of 01/15/2025.

While the business is global, the United States accounts for the majority of revenue because of the scale of the opioid epidemic and the maturity of reimbursement frameworks for addiction medicines. Indivior works closely with physicians, treatment centers and payers in the US to improve access to its therapies, according to Indivior press release as of 02/15/2024.

Management emphasizes a pipeline-driven approach, investing in both lifecycle management of existing brands and the development of next-generation formulations, including long-acting injectables and digital support tools. This strategy is designed to differentiate its portfolio and support pricing power in a competitive landscape, according to Indivior capital markets day materials as of 11/07/2024.

Beyond product sales, Indivior’s business model includes active engagement with policymakers and professional bodies to shape guidelines for evidence-based addiction treatment. The company is listed among significant lobbying spenders within the US pharmaceuticals and health products industry, reflecting its interest in the regulatory framework for opioid use disorder therapies, according to OpenSecrets overview as of 10/10/2024.

Main revenue and product drivers for Indivior PLC

Indivior’s revenue base is anchored by its opioid use disorder franchise, including sublingual and injectable formulations that help patients transition away from illicit opioid use. Key commercial brands have maintained a strong presence in the US addiction-treatment market, supported by clinical data and widespread physician familiarity, according to Indivior press release as of 02/13/2025.

In its full-year 2024 update, Indivior reported that net revenue for 2024 increased versus 2023 on the back of growth in long-acting injectable treatments for opioid use disorder and continued demand in the US, while some legacy products experienced more competitive pressure. The company also highlighted improved adjusted operating margins, reflecting a mix shift toward higher-value therapies, according to Indivior press release as of 02/13/2025.

The long-acting injectable portfolio is a strategic priority because it can offer more stable blood levels of medication and better adherence relative to daily dosing. These features are important in real-world addiction treatment, where missed doses can increase relapse risk. The company has invested in additional manufacturing and commercialization capabilities to support global expansion of these products, according to Indivior press release as of 09/12/2024.

Beyond currently marketed medicines, Indivior is advancing pipeline candidates targeting substance use disorders and related psychiatric conditions. These include new formulations aiming to improve convenience and reduce diversion risks, as well as potential treatments for other addictions. Such programs remain in various phases of clinical development and are part of the longer-term revenue opportunity, according to Indivior R&D update as of 06/18/2024.

The company’s commercial strategy emphasizes payer engagement, including negotiations with US commercial insurers, Medicaid programs and integrated health systems. Contracting and formulary positioning in these channels can influence volumes and net pricing, especially as generic competition and alternative therapies emerge, according to Indivior press release as of 02/15/2024.

Outside the US, Indivior is working to grow in Europe and selected international markets, though reimbursement pathways can be slower and more fragmented. International expansion contributes a smaller share of revenue today but is seen by management as a source of diversification over time, according to Indivior press release as of 02/13/2025.

Conclusion

Indivior PLC has positioned itself as a focused player in addiction treatment, with a revenue base heavily exposed to the US market and a strategic tilt toward long-acting injectable therapies. Recent financial updates underscore the importance of the opioid use disorder franchise and the contribution of newer formulations, while also highlighting competitive and policy sensitivities in this space. The company’s efforts to move its primary listing toward the US underscore its ambition to align more closely with the market where it generates most of its revenue and where investor interest in healthcare and specialty pharma remains deep. For US-focused investors, the stock represents an exposure to the intersection of public health needs, regulatory oversight and innovation in addiction medicine, without this article expressing any recommendation regarding the shares.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.